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Introduction
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia [1] and a major risk factor for ischemic stroke [2] . Anticoagulants -such as vitamin K antagonists and direct oral anticoagulants -can effectively reduce stroke risk [3, 4] , but their relative benefits and harms depend on the absolute risk of stroke while patients are off treatment, given that they inherently carry a risk of (major) bleeding complications. Previously, clinical decision rules have been developed to estimate stroke risk in AF patients, with the CHA2DS2-VASc rule being the most well-known example [5] . Published as an update to the CHADS2 rule [6] , CHA2DS2-VASc was first recommended in the 2010 European Society of Cardiology practice guideline [7] . Swift uptake into clinical practice followed, but subsequent validation studies showed ambiguous and conflicting results. This is exemplified, for instance, by the ongoing debate on the optimal threshold below which stroke risk is low enough for anticoagulation to be omitted [8] [9] [10] [11] [12] .
Therefore, the aim of the present study was to evaluate the current evidence base for the use of CHA2DS2-VASc to predict stroke in AF patients. For this purpose, we performed the following steps: (i) reviewed existing studies validating CHA2DS2-VASc for AF patients not (yet) anticoagulated; (ii) meta-analyzed estimates of the c-statistic and stroke risk per score; and (iii) explored sources of heterogeneity across the validation studies.
Methods
Throughout the planning and conduct of this systematic review, we followed the Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction (CHARMS) recommendations for framing the review question, critical appraisal, and data extraction for systematic reviews of prediction modeling studies [13] (see Table 1 for details).
The CHA2DS2-VASc score
The CHA2DS2-VASc clinical decision rule was developed in 2010 by Lip et al. as an update to the original CHADS2 rule [6] by the inclusion of additional predictors for stroke. Patients were assigned points for congestive heart failure (1 point), hypertension (1 point), age > 75 years (2 points), diabetes (1 point), prior stroke (2 points), age > 65 years (1 point), female sex (1 point), and vascular disease (1 point). Risk categories were defined according to the total sum of scored points, and consisted of 'low' (0 points), 'intermediate' (1 point), and 'high (≥ 2 points). With the use of these categories, the c-statistic was 0.61 (0.51-0.70) in the derivation cohort [5] (Data S1). No efforts were made to adjust the c-statistic for potential overoptimism [14] .
Data sources and search strategy
We performed a systematic search to identify all studies that validated the CHA2DS2-VASc rule in patients with non-valvular AF. MEDLINE and EMBASE were searched from 1 January 2001 to 1 March 2017. The search syntax was based on the broad Ingui search filter for identifying prediction studies [15] , and augmented with the filter by Geersing et al. [16] and the term 'Atrial Fibrillation' with its MeSH heading (Data S2). Crossreference checks were performed by using the reference lists of each selected article.
Study selection
As CHA2DS2-VASc was specifically developed to guide anticoagulant decision-making, notably for selecting AF patients for whom anticoagulant therapy can be safely withheld, we focused on studies validating this decision rule in AF patients not already treated with anticoagulants. To identify articles eligible for this review, the following inclusion criteria were used:
1 Original research articles on the external validation of CHA2DS2-VASc (i.e. validation in patients not used for the derivation of the score). 2 Adults aged > 18 years with non-valvular AF. 3 AF patients not yet treated with anticoagulation, or data presented separately for those not anticoagulated. Treatment with antiplatelet therapy was allowed. 4 Allowing for extraction of the c-statistic and/or absolute stroke or thromboembolic risks at different risk scores of CHA2DS2-VASc.
Studies including patient populations that dictate specific treatment decisions regardless of the score on a clinical decision rule, e.g. those after cardiac surgery, with mechanical heart valves or mitral valve stenosis, or after ablation or left appendage closure, were excluded.
A single reviewer (S.v.D.) performed the study selection and included all eligible articles after consensus with a second reviewer (G.J.G.).
If different articles used subsets of the same data source, the article on the patient population that was most representative of our study domain was included after consensus between reviewers, or after consultation with the corresponding authors when needed.
Critical appraisal and risk of bias assessment
We critically appraised the selected studies according to the CHARMS guidelines [13] . From the checklist, we identified 12 items that were relevant for external validation studies (see Table S1 for an overview). Two independent reviewers (S.v.D. and F.K.) scored the risk of bias for each item (no risk of bias, risk of bias, or unclear), and decided on a summary risk of bias estimate for which 
Data preparation
In accordance with previous recommendations, we rescaled the extracted c-statistic by applying the logit transformation [17] . If more than one c-statistic was reported, e.g. when calculated by use of the aforementioned risk categories or for a continuous score, the highest c-statistic was used. The error variance of the logit c-statistic was estimated from the reported confidence interval (CI) [18] or standard error (Delta method). If no information on uncertainty was reported, we used the approximation as reported by Debray et al. [17] . Furthermore, we rescaled annual stroke risk estimates by applying the square root transformation [19] . The corresponding variance was estimated by the use of Poisson approximations, with application of the Delta method [17] .
Data analysis
We applied random effects meta-analysis by using restricted maximum likelihood estimation to summarize estimates of model discrimination (logit c-statistic) and annual risk per score (square root risks) [17, 20] . In accordance with recent guidelines, CIs were calculated with the Hartung-Knapp-Sidik-Jonkman method [21] . We calculated approximate 95% prediction intervals (PIs) to ascertain the potential impact of between-study heterogeneity. These intervals indicate the range of performances (e.g. cstatistic or stroke rates per CHA2DS2-VASc score) that can be expected in future validation studies with similar characteristics as those included in our review. Additionally, we calculated the probability that the annual stroke risk was below a certain threshold if, in 'real-life' practice, the CHA2DS2-VASc rule assigned an AF patient a score of 0, 1, or 2 [22] .
Finally, we performed random effects meta-regression to investigate potential sources of heterogeneity. For study characteristics, we included the outcome under study, the number of person-years of follow-up and the dichotomized risk of bias as covariates. For summarized patient characteristics, covariates of interest were the mean age of the study population, proportion of females, mean CHA2DS2-VASc score, prevalence of heart failure, and prevalence of platelet inhibitor use (seee Table S3 and Figure S3A -D). All analyses were performed with the package METAFOR (univariate meta-analysis) version 1.9-8 in R 3.3.0.
Results

Included studies
The process of study selection is shown in Fig. 1 . The initial search yielded 17 667 results, from which 8096 duplicates were discarded. After reading titles and abstracts, we excluded 19 245 articles, primarily because these included patients outside the domain of interest (~60%), did not address risk prediction (~30%), or did not externally validate CHA2DS2-VASc (~5%).
In total, 126 studies were subjected to full-text evaluation. Inclusion criteria were not met for 107 of these, resulting in a final selection of 19 validation studies.
The key characteristics of each study are shown in Table 2 . Seven studies (with a total of 163 610 AF patients and a total of 365 501 person-years of follow-up) were performed in AF patients recruited from the general (unselected) population, and 12 studies (a total of 683 138 AF patients and a total of 1 738 930 personyears of follow-up) included a subsample of patients from the hospital care setting.
The outcomes under study consisted of: (i) ischemic stroke in 10 studies; (ii) all thromboembolic events in eight studies, i.e. ischemic strokes and systemic thromboembolism (defined as peripheral embolism in six studies, and peripheral embolism and/or pulmonary embolism in two studies); or (iii) all types of stroke (ischemic plus hemorrhagic stroke) in one study. Most studies originated from Europe and North America, and five were performed in East Asia. The number of included patients ranged from 154 to 198 697, and the follow-up time from 11 months to 53 months ( Table 2) .
Risk of bias
The risk of bias of the included studies is summarized in Fig. S1 . For details of individual studies, see Table S2 . Overall, two of seven studies performed in the general population were considered to be at risk of bias, as were the majority of studies enrolling patients from a hospital care setting. In general, the source of the data and the eligibility criteria caused no concern for bias. Some studies did not provide information on the use of antiplatelet therapy. This could induce biased results on the predictive accuracy of CHA2DS2-VASc, because, albeit to a limited extent, antiplatelet therapy may reduce the occurrence of stroke and thus cause an underestimation of the predictive accuracy of the rules [3] . The definition and measurement of the predictors -i.e. the variables included in the CHA2DS2-VASc score -and the outcome under study frequently differed across studies. Mostly, these were clearly defined. Predictors were mostly assessed blinded for the outcome. No study explicitly reported whether the outcomes were assessed blinded for the initial CHA2DS2-VASc score, potentially introducing bias for outcomes requiring subjective interpretation such as TIA [13] .
In six studies (two in unselected patients and four in selected patients), the number of outcome events was lower than the generally recommended~100 events for validation of a decision rule [42] . In addition, the amount and handling of missing data were unclear in the majority of studies. As data are seldom missing completely at random, inadequate handling of missing data could introduce bias [43] [44] [45] .
Meta-analysis of discriminative ability
In both populations, there was substantial between-study heterogeneity. In studies enrolling patients from the general population, we found an average c-statistic of 0.64 (95% CI 0.56-0.71). The variation in discriminative performance of CHA2DS2-VASc across studies is indicated in Figure S2A ,B, and is reflected by the wide approximate 95% PI, which that ranged from 0.45 to 0.79. In studies recruiting from a hospital care setting, we found a somewhat higher average c-statistic of 0.71 (95% CI 0.62-0.79). Again, the 95% PI was wide, ranging from 0.40 to 0.90. On the basis of 'eye-balling', we identified three outlying studies. When we excluded two studies with high c-statistics [24, 30] , summary estimates were similar to the results of studies in general population settings. After exclusion of one study with a low c-statistic [31] or all three outlying studies, discrimination remained highest in studies recruiting from hospitals, with a lower point estimate but more narrow 95% PIs (data not shown).
Meta-analysis of stroke risk per score Figure 2 shows the forest plots with the annual stroke risks and/or systemic thromboembolism for scores 0-3.
For every score on CHA2DS2-VASc, there was substantial heterogeneity in both settings of care, with wide approximate 95% PIs. In studies enrolling patients from the general population, for example, the stroke risk for a CHA2DS2-VASc score of 0 in a new validation study could lie between 0.0% and 0.9%. For scores of 1 and 2, these were 0.3% and 1.2%, and 0.4% and 3.3%, respectively ( Fig. 2A) .
Studies recruiting from a hospital care setting showed a more diverse distribution of risks per score, with higher pooled annual risks for all scores. For instance, the annual risk for a CHA2DS2-VASc score of 1 was 1.4% (approximate 95% PI 0.04-6.5%) in these studies, as compared with 0.7% (approximate 95% PI 0.3-1.2%) in studies enrolling AF patients from the general population (Fig. 2B) . Although exclusion of one outlier [31] of the hospital-based studies in a sensitivity analysis resulted in a lower risk for a CHA2DS2-VASc score of 1 of 1.2%, this was still nearly twice as high as the pooled estimate of studies enrolling patients from the general population. Furthermore, the PI remained wide, ranging from 0.06 to 3.8. The differences between study populations did not sufficiently explain heterogeneity (Fig. 2C) .
Excluding one study that recruited patients who were all aged ≥ 75 years [23] in an additional sensitivity analysis did not change the results. Two studies sampled from the same Clinical Practice Research Datalink data source and including the same patients multiple times in our meta-analysis cannot be ruled out. Excluding either the study by van den Ham [35] or the study by Allan [40] did not change our results (data not shown).
To further illustrate the interpretation of pooled stroke risks and their uncertainty (owing to estimation error and heterogeneity), we calculated the probabilities that patients with certain CHA2DS2-VASc scores would have an annual stroke risk of < 1%. For patients recruited from the general population, these probabilities were 98% (score of 0), 91% (score of ≤ 1), and 19% (score of ≤ 2). For patients recruited from a hospital care setting, these probabilities dropped to 71%, 39%, and 17%, respectively.
Meta-regression and best available evidence
To further explore sources of heterogeneity in both discrimination and the stroke risk per score, we performed several meta-regression analyses. These demonstrated that it was difficult to identify any relevant sources, as regression coefficients for risk of bias, study characteristics or summarized patient characteristics were not statistically significant. Furthermore, we explored heterogeneity between studies considered as 'best available evidence' (Table S3 ; Figure S3A-D) .
Discussion
This systematic review and meta-analysis thoroughly explores heterogeneity in the results of all currently available validation studies of CHA2DS2-VASc. Our analysis confirms that most validation studies of CHA2DS2-VASc yield conflicting results, with highly variable estimates for stroke risk per score. This heterogeneity partly appears to arise from population or case-mix differences across the validation studies, as stratified analyses showed lower stroke risk estimates for studies enrolling patients from the open general population than for studies using hospital-based recruitment strategies. However, substantial between-study heterogeneity remained and could not be resolved by adjusting for differences in study characteristics, differences in risk of bias, or other differences in population characteristics.
Strengths and limitations
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Also, the National Institute for Health and Care Excellence guidelines [49] provide a formal evaluation of CHA2DS2-VASc, and concluded the score provided a cost-effective method to estimate stroke risk and indicate anticoagulant treatment. However, stroke risks were based on a single study [50] and no summary estimate was provided, so a measure of uncertainty was lacking.
Nevertheless, for full appreciation of our results several issues should be considered. The CHA2DS2-VASc rule has been advocated as being superior to its precursor CHADS2 in identifying AF patients at 'truly low' risk of stroke, in particular for those with low scores on CHA2DS2-VASc (0 or 1). However, prompted by validation studies of CHA2DS2-VASc showing widely varying results, there has been much debate about what score (in particular 0 or 1) truly defines low risk. This is reflected in our meta-analysis. Indeed, we found that future validation studies in which patient enrollment starts in hospital care may observe a very low stroke risk for a CHA2DS2-VASc score of 0 (well below 1%, the threshold above which it is often advocated that the benefits of anticoagulants outweigh the bleeding risk [51, 52] ). However, patients with a score of 1, 2 or even 3 may also be found to have such a low stroke risk. Conversely, future studies may also, in fact, find a high stroke risk (e.g. > 3%) in patients with a score of 0, which we believe explains the confusion and recent debate on what score denotes a low risk [8, 9, [53] [54] [55] .
We made many efforts to explore possible sources of this large extent of between-study heterogeneity, and several issues require further inspection. First, our results suggest that differences in the risk of bias do not play an important role when estimates of prediction model performance are summarized. Although several validation studies showed shortcomings, the differences were small, and even the most homogeneous group of studies at low risk of bias showed conflicting results for stroke risk per score.
Second, some heterogeneity could be explained by differences in case-mix across the validation studies. We observed a clinically relevant higher stroke risk in studies recruiting AF patients from a hospital care setting than in those enrolling from the general population. It is possible that AF patients recruited from the hospital care setting represent more diseased patients with a higher baseline risk of stroke, independently of their overall CHA2DS2-VASc score. As an example, the type and burden of AF (paroxysmal, persistent, or permanent) may have an association with stroke risk [56] , as may the severity and duration of a patient's individual CHA2DS2-VASc risk factors, or risk factors not included in the CHA2DS2-VASc score, such as renal failure [57] .
Case-mix differences in such risk factors between patients sampled from hospital care and from the general population could, at least partly, explain the variation in validation studies and the observed difference in stroke risk in our results.
Third, although we stratified studies to the clinical setting in which patient enrollment started, this strategy did not sufficiently explain all heterogeneity across the validation studies. Adjustment for differences in study characteristics through meta-regression did not much affect the extent of between-study heterogeneity. For instance, the definition of the outcome under study -only ischemic stroke, ischemic stroke and thromboembolism, or indeed even any type of stroke, including intracranial hemorrhage -could potentially influence the risks for each CHA2DS2-VASc score, but including the different outcomes as a covariate in the meta-regression model did not affect the results. Similarly, additional summarized population characteristics, such as mean CHA2DS2-VASc score or the use of platelet inhibitors, did not account for the heterogeneous results. Importantly, we could not evaluate which combination of predictors contributed to a patient's CHA2DS2-VASc score. It is believed that not all predictors in CHA2DS2-VASc carry the same stroke risk [58, 59] , although this is not acknowledged in the rule, as almost all of its predictors contribute 1 point. Likewise, females with a score of 1 (i.e. no other risk factor) are likely to be at lower risk than males with one risk factor. However, the included validation studies often do not report stratified analyses for males and females, and thus, in this meta-analysis of aggregated data, we were unable to account for this. Individual patient data meta-analysis would be needed to fully clarify issues such as stroke risk in females with no additional stroke risk factors.
Fourth, the age categories of CHA2DS2-VASc are broad, and thus a patient aged 65 years will receive the same score as one aged 74 years for the 'Age' category, although the stroke risk will probably not be equal. This also results in the heterogeneity and variation found in the results of validation studies.
Fifth, it has previously been shown that ethnicity has an effect on stroke risk [60, 61] and stroke mortality [62] . Unfortunately, we did not have enough data on ethnicity to consider this variable in our meta-analysis. We did, however, include the geographic region as a covariate in the meta-regression model (data not shown), and, in line with the findings of Quinn et al. [48] , this was not sufficient to explain the large heterogeneity.
Sixth, we were only able to meta-analyze the stroke risk per score and the c-statistic, as these are the measures that are most often and consistently reported in current validation studies. Other measures, such as decision curve analysis, have been proposed to better investigate the clinical value of using a decision rule [63, 64] . Unfortunately, these aspects of model performance are rarely consistently quantified. This makes meta-analyzing such measures difficult, if not (yet) impossible, and can be considered to be a limitation of this current systematic review and meta-analysis of pooled c-statistics and strokes risks per score.
Furthermore, it is important to consider that we only included validation studies in which patients were not (yet) using anticoagulants. By itself, the choice of including only patients not receiving anticoagulation could result in a selected subtype of AF patients, as this may have led to confounding 'by contraindication' [65] when anticoagulation was withheld because of (for instance) severe illness or bleeding risk. However, we deliberately chose not to include populations already receiving anticoagulants, as CHA2DS2-VASc is intended to be used for stroke risk prediction prior to anticoagulant treatment decisions in AF patients.
Finally, it should be noted that, essentially, heterogeneity is not uncommon for studies validating diagnostic or prognostic decision rules, including in the field of thrombotic disorders. Clinical decision rules such as CHA2DS2-VASc are popular in daily clinical practice, because they are helpful and easy-to-apply methods for tailoring subsequent treatment decisions. Indeed, for younger patients without additional stroke risk factors (score of 0) and for more 'high-risk' patients (score of 2-3 or above), CHA2DS2-VASc clearly helps in making anticoagulant treatment decisions. However, on the basis of a synthesis of the current evidence in the literature, tailoring treatment for patients at 'low to intermediate risk' (i.e. CHA2DS2-VASc scores of 1-2) remains ambiguous, as is also reflected by the discussion in literature on the optimal threshold for initiating anticoagulant treatment [8] [9] [10] [11] [12] .
Clinical implications and future research questions
In the treatment of AF, adequate identification of different stroke risk groups is pivotal for anticoagulant treatment decisions. The main inference of our meta-analysis is that although CHA2DS2-VASc is a simple, effective and easy-to-use tool for truly low-risk and truly high-risk patients, it may have difficulties in tailoring anticoagulant treatment adequately in AF patients at intermediate risk of stroke (roughly those with a score of 1 or 2). Differences in stroke risks between studies recruiting from hospitals and from the general population indicate that possible case-mix differences between populations should be taken into account in clinical decision-making, but further uncertainty remains. Future research should focus on this issue, with further model revision, and considering additional comorbidity items (e.g. renal impairment), (novel) biomarkers, or imaging such as left atrial wall remodeling patterns, in addition to existing prediction models for quantifying thrombotic risk in AF patients. [66] [67] [68] . These additional tests may ultimately result in a better clinical decision. Whether this can be achieved should be the focus of further investigation.
Conclusions
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